Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (374)
  2. Journal Article (226)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (639)
  2. Solid Tumor Oncology Division (639)
  3. Thoracic Oncology (639)
  4. Department of Pathology and Laboratory Medicine (210)
  5. GSK Faculty (191)
  6. Hematology-Oncology Fellows (186)

More Groups

People
  1. Marc Ladanyi (123)
  2. Mark Kris (91)
  3. Maria Arcila (83)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (23)
  2. 2024 (61)
  3. 2023 (68)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (85)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (119)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (78)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Larotrectinib compared with real-world non-tropomyosin receptor kinase inhibitor therapies in patients with tropomyosin receptor kinase fusion cancer
    Journal Article

    Brose, M. S.; Westphalen, C. B.; Pan, X.; Bernard-Gauthier, V.; Kurtinecz, M.; Guo, H.; Aris, V.; Brett, N. R.; Majdi, A.; Subbiah, V.; more...
    JCO Precision Oncology (2025)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer
    Journal Article

    Hong, D. S.; Xu, R. H.; Shen, L.; Dierselhuis, M. P.; Orbach, D.; McDermott, R.; Italiano, A.; Tahara, M.; Bernard-Gauthier, V.; Neu, N.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Diverse ERBB2/ERBB3 activating alterations and coalterations have implications for HER2/3-targeted therapies across solid tumors
    Journal Article

    Liu, D.; Jee, J.; Drilon, A.; Heilmann, A. M.; Allen, J. M.; Schrock, A. B.; Keller-Evans, R. B.; Li, B. T.
    Cancer Research Communications (2025)

    Fulltext@MSK | Save
  • Dual Targeting of RET and SRC to Treat RET-Positive Non-Small Cell Lung Cancer
    Meeting Abstract

    Son, J.; Rix, L. L. R.; Fang, B.; Welsh, E. A.; Drilon, A.; Koomen, J. M.; Cocco, E.; Rix, U.
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Efficacy outcomes of larotrectinib by prior therapy and performance status in patients with TRK fusion lung cancer
    Meeting Abstract

    Moreno Garcia, V.; Drilon, A.; Kummar, S.; Lin, J. J.; Tan, D. S. W.; Rieke, D. T.; Dubashi, B.; Kunhiparambath, H.; Burcoveanu, D. I.; Neu, N.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Genetic ancestry-based differences in biomarker-based eligibility for precision oncology therapies
    Journal Article

    Arora, K.; Suehnholz, S. P.; Zhang, H.; Ostrovnaya, I.; Kundra, R.; Nandakumar, S.; Nissan, M. H.; Brannon, A. R.; Bandlamudi, C.; Ladanyi, M.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions
    Review

    Desilets, A.; Repetto, M.; Yang, S. R.; Drilon, A.
    Cancer (2025)

    Fulltext@MSK | Save
  • Population-adjusted indirect treatment comparisons of repotrectinib among patients with ROS1+ NSCLC
    Journal Article

    Wolf, J.; Goring, S.; Lee, A.; Cho, B. C.; Drilon, A.; Yuan, Y.; Ayers, D.; Lozano-Ortega, G.; Korol, E. E.; Korpach, S. G.; more...
    Cancers (2025)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
    Journal Article

    Qi, C.; Shen, L.; Andre, T.; Chung, H. C.; Cannon, T. L.; Garralda, E.; Italiano, A.; Rieke, D. T.; Liu, T.; Burcoveanu, D. I.; more...
    European Journal of Cancer (2025)

    Fulltext@MSK | Save
  • Efficacy of zenocutuzumab in NRG1 fusion-positive cancer
    Journal Article

    Schram, A. M.; Goto, K.; Kim, D. W.; Macarulla, T.; Hollebecque, A.; O'Reilly, E. M.; Ou, S. H. I.; Rodon, J.; Rha, S. Y.; Nishino, K.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save